Samsung has announced a partnership with Alcedis, a clinical research organization that specializes in data-driven trials, to make wearable-collected health data useful in formal clinical research settings. The goal is to help pharmaceutical companies and other research organizations get more value from continuous, real-world health monitoring without the cost and time burdens that typically slow down clinical trials.

Wearables have become cheap and widely available, which makes them attractive for researchers who want data from patients outside of clinical settings. The problem is that collecting a signal is one thing. Turning it into evidence that holds up scientifically is quite another. That gap between raw biometric data and clinically meaningful endpoints has been a persistent obstacle for research teams trying to use consumer devices in serious medical studies.

Samsung’s pitch is that it can bridge that gap by combining hardware, software, and research infrastructure in one package. Its Galaxy Watch line already carries sensors cleared for medical use, including tools for detecting sleep apnea and atrial fibrillation. Under this partnership, those capabilities get paired with Alcedis’s experience running clinical trials and managing participant engagement.

The technical setup Samsung brings to the table includes:

• Blood oxygen (SpO2) measurement via Galaxy Watch sensors
• An FDA-cleared sleep apnea detection feature for adults 22 and older
• An ECG Monitor App that can flag irregular heart rhythms suggestive of AFib
• Fine-grained biosensor control for study-specific configurations
• Access to participant-level and device-level data within established research protocols

The division of labor in the partnership is straightforward. Alcedis handles study execution and keeps participants engaged throughout the trial. Samsung provides the devices, sensors, and the underlying research platform that captures and organizes the data.

This kind of deal reflects a broader shift happening across the medical research world. Regulators and pharmaceutical companies are increasingly open to digital endpoints, meaning health measurements taken by devices rather than clinicians in a hospital. That opens the door for wearables to play a real role in trials, but only if the data collection is rigorous and the methodology is defensible. That is exactly the problem this partnership is trying to solve.

Samsung has been building its health research credentials for a while. The company recently published a study on using Galaxy Watch data to predict fainting episodes, which shows it is pursuing clinical validation for its sensors beyond marketing claims. Pairing that research focus with an established CRO like Alcedis gives Samsung a credible path to seeing its devices used in regulated trials.

For the pharmaceutical industry, the appeal is speed and cost. Traditional clinical endpoints often require expensive in-clinic visits and specialized equipment. If a Galaxy Watch can capture the same signal continuously and passively, trial timelines could shrink and costs could drop. That is a meaningful incentive for drug developers, especially in therapeutic areas like cardiology, respiratory health, and sleep medicine where continuous monitoring adds real value.

There are limits worth noting. Samsung’s sleep apnea feature is not intended for people already diagnosed with the condition, and neither the ECG app nor the sleep feature is meant to replace clinical diagnosis. The data they generate is designed to support research, not replace physician judgment. Those boundaries matter when evaluating what this partnership can realistically deliver.

Still, the direction is clear. Consumer health devices are moving closer to the clinic, and partnerships like this one are part of how that happens.